Form 4: Precision BioSciences CEO Michael Amoroso Reports Stock Transactions
SEC Form 4 Filing
Michael Amoroso, President and CEO of Precision BioSciences, reports the vesting and sale of common stock to cover tax obligations.
Summary
- Michael Amoroso, the President and CEO of Precision BioSciences, reported transactions involving the company's common stock.
- On May 1, 2024, 3,417 Restricted Stock Units (RSUs) vested and were settled.
- On May 2, 2024, 1,526 shares were sold at a weighted average price of $10.32 to cover tax withholding obligations.
- Following these transactions, Amoroso directly owns 13,772 shares of Precision BioSciences common stock and 3,417 RSUs.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 24, 2022.
- The reported amounts of securities have been adjusted to reflect a 1-for-30 reverse stock split that occurred on February 13, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to stock options and tax obligations, without indicating any significant positive or negative developments for the company.
Positives
- The transactions were part of a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned and not based on insider information.
- The sale of shares was specifically to cover tax obligations, indicating a responsible approach to managing equity compensation.
Future Outlook
There is no future outlook provided in this document.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
- The use of Rule 10b5-1 plans is a common strategy among executives to avoid accusations of insider trading, allowing them to sell shares at predetermined times and prices.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
- The use of a Rule 10b5-1 plan can reassure investors that insider trading is being avoided.
Key Dates
| Date | Description |
|---|---|
| 2022-03-21 | Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023. |
| 2022-03-24 | Rule 10b5-1 plan adopted. |
| 2023-03-21 | First vesting date of RSUs. |
| 2024-02-13 | 1-for-30 reverse stock split effected. |
| 2024-03-21 | Partial vesting of Restricted Stock Units. |
| 2024-05-01 | Settlement of vested RSUs. |
| 2024-05-02 | Sale of shares to cover tax withholding obligations. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.